Last updated on December 2017

Combined Phase 3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease


Brief description of study

This study is designed to evaluate the effect of treatment with filgotinib on the induction and maintenance of remission in subjects with moderately to severely active Crohn's disease (CD).

Clinical Study Identifier: TX155023

Contact Investigators or Research Sites near you

Start Over

Jo-Anne E. Tiamzon, BS, CCRC

Gastroenterology Associates of Tidewater
Chesapeake, VA USA
  Connect »